Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer
Meriem Mokhtech(Yale University), Krishan R. Jethwa(Mayo Clinic), Christopher J. Anker(University of Vermont), Amol Narang(Johns Hopkins University), Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael Cecchini(Yale Cancer Center), Kimberly L. Johung(Yale University), Salma K. Jabbour(Rutgers, The State University of New Jersey), Michael G. Haddock(Mayo Clinic in Arizona), John W. Kunstman(University of New Haven), Stacey Stein(Yale University), Joseph M. Herman(Northwell Health), Joseph A. Miccio(Penn State Milton S. Hershey Medical Center)
Cited by 6
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism
|Nature Genetics|2013|621
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Pancreatic Adenocarcinoma, Version 2.2012
|Journal of the National Comprehensive Cancer Network|2012|304